Idiopathic intracranial hypertension in a pediatric transgender patient

Purpose: Androgens given for gender affirmation have been implicated in the pathophysiology of idiopathic intracranial hypertension (IIH) in transgender patients. 10 cases of transgender adults with IIH have been published but this association has not been described in younger patients. Herein we de...

Full description

Bibliographic Details
Main Authors: Taylor Nayman, Mélanie Hébert, Luis H. Ospina
Format: Article
Language:English
Published: Elsevier 2021-12-01
Series:American Journal of Ophthalmology Case Reports
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2451993621002176
id doaj-2e7dbfed92c84c7aa407f0bf406fb0b2
record_format Article
spelling doaj-2e7dbfed92c84c7aa407f0bf406fb0b22021-09-25T05:09:23ZengElsevierAmerican Journal of Ophthalmology Case Reports2451-99362021-12-0124101208Idiopathic intracranial hypertension in a pediatric transgender patientTaylor Nayman0Mélanie Hébert1Luis H. Ospina2Department of Ophthalmology, Centre hospitalier universitaire Sainte-Justine, 3175 Chemin de la Côte-Sainte-Catherine, Montréal, QC, H3T 1C5, CanadaFaculty of Medicine, Université de Montréal, 2900 Edouard Montpetit Blvd, Montreal, Quebec, H3T 1J4, CanadaDepartment of Ophthalmology, Centre hospitalier universitaire Sainte-Justine, 3175 Chemin de la Côte-Sainte-Catherine, Montréal, QC, H3T 1C5, Canada; Corresponding author. Department of Ophthalmology, Centre hospitalier universitaire Sainte-Justine, 3175 Chemin de la Côte-Sainte-Catherine, Montreal, Quebec, H3T 1C5, Canada.Purpose: Androgens given for gender affirmation have been implicated in the pathophysiology of idiopathic intracranial hypertension (IIH) in transgender patients. 10 cases of transgender adults with IIH have been published but this association has not been described in younger patients. Herein we describe the first case of IIH in an adolescent transgender patient. Observations: A 17-year-old non-obese female-to-male transgender patient on subcutaneous testosterone since age 13 presented with a two-month history of transient visual obscuration and frontal headaches. Ophthalmological examination revealed Frisen grade 2 papilledema with preserved visual function. Lumbar puncture confirmed elevated opening pressure. Papilledema resolved with oral acetazolamide and reduction of testosterone therapy. Conclusions and Importance: The use of cross-sex hormone therapy (CSH) for gender affirmation may increase the risk of IIH. Awareness of this association is important as the number of younger transgender patients seeking CSH is increasing significantly.http://www.sciencedirect.com/science/article/pii/S2451993621002176Idiopathic intracranial hypertensionPediatricTransgenderHormone therapyAndrogensPapilledema
collection DOAJ
language English
format Article
sources DOAJ
author Taylor Nayman
Mélanie Hébert
Luis H. Ospina
spellingShingle Taylor Nayman
Mélanie Hébert
Luis H. Ospina
Idiopathic intracranial hypertension in a pediatric transgender patient
American Journal of Ophthalmology Case Reports
Idiopathic intracranial hypertension
Pediatric
Transgender
Hormone therapy
Androgens
Papilledema
author_facet Taylor Nayman
Mélanie Hébert
Luis H. Ospina
author_sort Taylor Nayman
title Idiopathic intracranial hypertension in a pediatric transgender patient
title_short Idiopathic intracranial hypertension in a pediatric transgender patient
title_full Idiopathic intracranial hypertension in a pediatric transgender patient
title_fullStr Idiopathic intracranial hypertension in a pediatric transgender patient
title_full_unstemmed Idiopathic intracranial hypertension in a pediatric transgender patient
title_sort idiopathic intracranial hypertension in a pediatric transgender patient
publisher Elsevier
series American Journal of Ophthalmology Case Reports
issn 2451-9936
publishDate 2021-12-01
description Purpose: Androgens given for gender affirmation have been implicated in the pathophysiology of idiopathic intracranial hypertension (IIH) in transgender patients. 10 cases of transgender adults with IIH have been published but this association has not been described in younger patients. Herein we describe the first case of IIH in an adolescent transgender patient. Observations: A 17-year-old non-obese female-to-male transgender patient on subcutaneous testosterone since age 13 presented with a two-month history of transient visual obscuration and frontal headaches. Ophthalmological examination revealed Frisen grade 2 papilledema with preserved visual function. Lumbar puncture confirmed elevated opening pressure. Papilledema resolved with oral acetazolamide and reduction of testosterone therapy. Conclusions and Importance: The use of cross-sex hormone therapy (CSH) for gender affirmation may increase the risk of IIH. Awareness of this association is important as the number of younger transgender patients seeking CSH is increasing significantly.
topic Idiopathic intracranial hypertension
Pediatric
Transgender
Hormone therapy
Androgens
Papilledema
url http://www.sciencedirect.com/science/article/pii/S2451993621002176
work_keys_str_mv AT taylornayman idiopathicintracranialhypertensioninapediatrictransgenderpatient
AT melaniehebert idiopathicintracranialhypertensioninapediatrictransgenderpatient
AT luishospina idiopathicintracranialhypertensioninapediatrictransgenderpatient
_version_ 1717368958438342656